ClearPoint Neuro (NASDAQ:CLPT) Given New $20.00 Price Target at B. Riley Financial

ClearPoint Neuro (NASDAQ:CLPT) had its price objective increased by B. Riley Financial from $18.00 to $20.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $14.50.

ClearPoint Neuro Stock Down 14.0%

ClearPoint Neuro stock opened at $9.60 on Wednesday. The firm has a market capitalization of $272.83 million, a price-to-earnings ratio of -10.55 and a beta of 1.02. The firm’s fifty day moving average price is $13.14 and its two-hundred day moving average price is $15.62. ClearPoint Neuro has a 1-year low of $8.63 and a 1-year high of $30.10. The company has a current ratio of 6.37, a quick ratio of 5.56 and a debt-to-equity ratio of 1.84.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Tuesday, March 17th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). ClearPoint Neuro had a negative return on equity of 137.80% and a negative net margin of 69.08%.The business had revenue of $10.41 million for the quarter, compared to the consensus estimate of $10.40 million. On average, equities research analysts predict that ClearPoint Neuro will post -0.66 earnings per share for the current fiscal year.

Insider Transactions at ClearPoint Neuro

In other ClearPoint Neuro news, CEO Joseph Burnett sold 20,000 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $16.12, for a total value of $322,400.00. Following the completion of the transaction, the chief executive officer owned 11,565 shares in the company, valued at $186,427.80. This represents a 63.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On ClearPoint Neuro

Hedge funds and other institutional investors have recently made changes to their positions in the stock. MGO One Seven LLC increased its holdings in ClearPoint Neuro by 6.0% during the third quarter. MGO One Seven LLC now owns 19,026 shares of the company’s stock worth $415,000 after buying an additional 1,077 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in ClearPoint Neuro by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 65,557 shares of the company’s stock valued at $897,000 after acquiring an additional 1,109 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of ClearPoint Neuro by 4.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,791 shares of the company’s stock valued at $367,000 after acquiring an additional 1,204 shares during the period. Financial Management Professionals Inc. bought a new position in shares of ClearPoint Neuro during the 3rd quarter valued at approximately $28,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of ClearPoint Neuro during the 4th quarter worth approximately $25,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about ClearPoint Neuro

Here are the key news stories impacting ClearPoint Neuro this week:

• Positive Sentiment: B. Riley raised its price target to $20 and kept a “buy” rating, signaling analyst conviction in ClearPoint’s longer-term upside. Benzinga
• Positive Sentiment: Company reported record revenue and is integrating the IRRAS acquisition as part of its growth strategy, which management says supports longer-term revenue expansion. Press Release
• Neutral Sentiment: Q4 revenue came in essentially flat with expectations at $10.41M vs. a $10.40M consensus, limiting upside from the top line. Zacks
• Neutral Sentiment: Earnings call transcript and supplemental commentary are available for investors who want management’s details on guidance, integration plans, and margin trajectory. Earnings Transcript
• Negative Sentiment: Q4 EPS missed expectations: a loss of $0.27/share versus the consensus loss of $0.22, increasing near-term profitability concerns. MarketBeat
• Negative Sentiment: FY26 revenue guidance of $52M–$56M came in below some analysts’ expectations, which Seeking Alpha says triggered the steep selloff as investors reprice growth assumptions. Seeking Alpha

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.